Tirzepatide is a once-weekly injection of glucose-dependent dual agonists of GIP and GLP-1 receptors. In May 2022, Tirzepatide received FDA approval for the treatment of type 2 diabetes, becoming the first FDA-approved GIP and GLP-1 receptor agonists.
Basic Information
Chinese Name:替尔泊肽
English name: Tirzepatide
Product number: GT-L007
CAS number: 2023788-19-2
Sequence: Tyr-{Aib}-glu-gly-thr-phe-thr-ser-asp-tyr-ser-ile-{aib}-leu-asp-lys-ile-ala-gln-{diacid-gamma-glu-(AEEA)2-lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Molecular Formula: C225H348N48O68
Molecular weight: 4813.45
Tirzepatide was originally intended to address the long-term blood sugar control problems faced by people with type 2 diabetes. Promote insulin secretion by stimulating the activity of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin metabolism promoting polypeptide (GIP), relieve gastric emptying, and lower blood sugar. This dual agonist is designed to give Tirzepatide a unique advantage in controlling blood sugar.
Weekly injections are one of the characteristics of Tirzepatide. Compared to other drugs that require daily or multiple injections, weekly injections are more convenient for patients to accept and use. In addition, Tirzepatide has few side effects and low risk, which has attracted much attention in clinical practice.
However, although Tirzepatide has shown good efficacy and safety in clinical trials, further research is needed to evaluate its performance and potential risks for long-term use. Therefore, before using Tirzepatide, patients should fully communicate with their doctor to understand its indications, dosage and possible adverse reactions, and follow the doctor's advice for treatment.
In general, Tirzepatide, as a dual agonist of glucose-dependent GIP and GLP-1 receptors, provides a new treatment option for patients with type 2 diabetes. With the implementation of clinical practice, I believe that there will be more innovative drugs in the future that will bring better quality of life and smelting to diabetics.
Goodon Biotech can provide:
Tirzepatide intermediates
Tirzepatide drug impurities
Tirzepatide API raw materials
Post time: 2025-08-13